{"id":18005,"date":"2024-03-11T18:46:03","date_gmt":"2024-03-11T17:46:03","guid":{"rendered":"https:\/\/www.hematostat.net\/?p=18005"},"modified":"2024-04-09T16:48:46","modified_gmt":"2024-04-09T14:48:46","slug":"jakavi-ruxolitinib-est-desormais-remboursee-et-disponible-en-ville-et-a-lhopital-pour-les-patients-ages-de-12-ans-et-plus-atteints-de-gvhd-aigue-ou-chronique-cortico-refractaires","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/jakavi-ruxolitinib-est-desormais-remboursee-et-disponible-en-ville-et-a-lhopital-pour-les-patients-ages-de-12-ans-et-plus-atteints-de-gvhd-aigue-ou-chronique-cortico-refractaires\/","title":{"rendered":"JAKAVI\u00ae (ruxolitinib) est d\u00e9sormais rembours\u00e9e et disponible en ville et \u00e0 l&#8217;h\u00f4pital pour les patients \u00e2g\u00e9s de 12 ans et plus atteints de GvHD aigu\u00eb ou chronique cortico-r\u00e9fractaires."},"content":{"rendered":"<p><em><strong>Maladie du greffon contre l&#8217;h\u00f4te (GvHD)<\/strong><\/em><br \/>\n<strong>JAKAVI<sup>\u00ae<\/sup>\u00a0est indiqu\u00e9 dans le traitement des patients \u00e2g\u00e9s de 12 ans et plus atteints de la maladie du greffon contre l&#8217;h\u00f4te aigu\u00eb ou de la maladie du greffon contre l&#8217;h\u00f4te chronique qui ont une r\u00e9ponse inad\u00e9quate aux corticost\u00e9ro\u00efdes ou \u00e0 d&#8217;autres traitements syst\u00e9miques<sup>1<\/sup><\/strong><\/p>\n<p><em><strong>Place dans la strat\u00e9gie th\u00e9rapeutique :<\/strong><\/em><br \/>\nLa sp\u00e9cialit\u00e9 JAKAVI<sup>\u00ae<\/sup> (ruxolitinib) est un traitement de premi\u00e8re intention dans la strat\u00e9gie de prise en charge des patients \u00e2g\u00e9s de 12 ans et plus atteints de la maladie du greffon contre l&#8217;h\u00f4te aigu\u00eb ou de la maladie du greffon contre l&#8217;h\u00f4te chronique qui ont une r\u00e9ponse inad\u00e9quate aux corticost\u00e9ro\u00efdes ou \u00e0 d&#8217;autres traitements syst\u00e9miques<sup>2<\/sup>.<\/p>\n<p>&nbsp;<\/p>\n<p>1. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit Jakavi<sup>\u00ae<\/sup><br \/>\n2. HAS. Avis de la Commission de Transparence du 19 octobre 2022<\/p>","protected":false},"excerpt":{"rendered":"<p>Maladie du greffon contre l&#8217;h\u00f4te (GvHD) JAKAVI\u00ae\u00a0est indiqu\u00e9 dans le traitement des patients \u00e2g\u00e9s de 12 ans et plus atteints de la maladie du greffon contre l&#8217;h\u00f4te aigu\u00eb ou de [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[441],"class_list":["post-18005","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-admin6779"],"aioseo_notices":[],"authors":[{"term_id":441,"user_id":1,"is_guest":0,"slug":"admin6779","display_name":"HematoStat.net","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/4f64711e55fa3c9401676697c4783cec15305a6f940a0f120048b6141a611347?s=96&d=mm&r=g","first_name":"HematoStat.net","last_name":"","user_url":"http:\/\/www.hematostat.net","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/18005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=18005"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/18005\/revisions"}],"predecessor-version":[{"id":18006,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/18005\/revisions\/18006"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=18005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=18005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=18005"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=18005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}